Filing Flows › Incyte (INCY) › Q3 2026 › vs Q3 2025
Incyte (INCY) Q3 2026 vs Q3 2025 (year over year)
Incyte's revenue rose $191M (+14%) from $1.4B in Q3 2025 to $1.6B in Q3 2026. The biggest changes: Net sales +$127M (+11%); ZYNYZ +$35.7M (+157%); NIKTIMVO +$21.5M (+47%).
Incyte, Q3 2026: revenue $1.6B (+14% year over year), operating margin -45.5%, net loss $785M, operating cash flow −$675M. The chart draws each line against Q3 2025, the increases inside each band.
Every line
| Line | Q3 2026 | Q3 2025 | Change | % |
|---|---|---|---|---|
| JAKAFI | $827M | $791M | $35.4M | +4% |
| OPZELURA | $255M | $188M | $66.9M | +36% |
| JAKAVI | $132M | $126M | $6.8M | +5% |
| MINJUVI/MONJUVI | $54.6M | $42.0M | $12.6M | +30% |
| Milestone and contract revenues | $49.8M | $45.0M | $4.8M | +11% |
| Net sales | $1.3B | $1.2B | $127M | +11% |
| NIKTIMVO | $67.4M | $45.8M | $21.5M | +47% |
| ZYNYZ | $58.3M | $22.7M | $35.7M | +157% |
| OLUMIANT | $39.1M | $37.1M | $1.9M | +5% |
| ICLUSIG | $33.5M | $37.6M | −$4.1M | -11% |
| PEMAZYRE | $21.2M | $22.7M | −$1.6M | -7% |
| Other | $12.6M | $1.9M | $10.8M | +582% |
| TABRECTA | $6.8M | $6.5M | $320K | +5% |
| Revenue | $1.6B | $1.4B | $191M | +14% |
| Other income, net | $19.5M | $38.8M | −$19.3M | -50% |
| Net loss | $785M | −$424M | $1.2B | — |
| Costs & expenses | $2.4B | $1.4B | $957M | +68% |
| Operating costs | $2.3B | $922M | $1.3B | +146% |
| Income tax | $96.0M | $58.1M | $37.8M | +65% |
| Operating cash sources | $785M | −$424M | $1.2B | — |
| Depreciation & amortization | $24.2M | $24.0M | $152K | +0.6% |
| Share-based compensation | $69.8M | $61.6M | $8.2M | +13% |
| Working capital & other | $15.5M | $49.6M | −$34.1M | -69% |
| Cash used in operations | $675M | −$559M | $1.2B | — |
| Net loss absorbed | $785M | −$424M | $1.2B | — |
Questions
How much did Incyte's revenue grow year over year in Q3 2026?
Incyte's revenue rose $191M (+14%) from $1.4B in Q3 2025 to $1.6B in Q3 2026.
What drove Incyte's revenue change in Q3 2026?
Net sales +$127M (+11%); ZYNYZ +$35.7M (+157%); NIKTIMVO +$21.5M (+47%).